AbbVie Acquires Rights to Ichnos Glenmark’s Lead Myeloma Antibody (ISB 2001) in $1.93 Billion Deal

AbbVie will pay $700 million upfront to Ichnos Glenmark for exclusive rights to ISB 2001, a first-in-class trispecific antibody targeting multiple myeloma, in North America, Europe, Japan, and China123.

Additional milestone payments could bring the deal's total value to $1.93 billion, with Ichnos Glenmark also eligible for royalties on future sales1.

ISB 2001 simultaneously targets CD3 on T cells and two antigens on myeloma cells (BCMA and CD38), aiming for enhanced cancer cell killing and potential to overcome drug resistance12.

In Phase 1 trials, ISB 2001 demonstrated a 79% overall response rate and a 30% complete/stringent complete response rate in patients with relapsed or refractory multiple myeloma, along with a favorable safety profile12.

The FDA has granted ISB 2001 both Orphan Drug and Fast Track designations, expediting its clinical development1.

Under the agreement, Glenmark retains responsibility for development, manufacturing, and commercialization in emerging markets; AbbVie will oversee these activities in its licensed territories13.

Sources:

1. https://www.biopharmadive.com/news/abbvie-ichnos-glenmark-trispecific-myeloma-deal/752667/

2. https://medcitynews.com/2025/07/abbvie-multiple-myeloma-cancer-trispecific-antibody-bcma-cd38-cd3-igi-therapeutics-abbv/

3. https://iginnovate.com/2025/07/10/ichnos-glenmark-innovation-igi-announces-global-commercialization-strategy-for-isb-2001-following-licensing-deal-with-abbvie/